PCSK7 and metabolic dysfunction-associated steatotic liver disease: Recently, Dongiovanni et al. demonstrated that Proprotein Convertase Subtilisin/Kexin Type 7 (PCSK7) rs236918 G>C variant impacts on circulating lipids and liver damage in a large cohort of NAFLD patients [90].